标题:TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas
作者:Wang, Kun; Liu, Tiantian; Liu, Li; Liu, Jikai; Liu, Cheng; Wang, Chang; Ge, Nan; Ren, Hongbo; Yan, Keqiang; Hu, Sanyuan; Bjorkholm 更多
作者机构:[Wang, Kun; Liu, Jikai; Ren, Hongbo; Yan, Keqiang; Fan, Yidong] Shandong Univ, Dept Urol, Qilu Hosp, Jinan 250100, Peoples R China.; [Wang, Kun; Liu 更多
通讯作者:Xu, DW
通讯作者地址:[Xu, DW]Karolinska Univ Hosp Solna, Div Hematol, Dept Med, Stockholm, Sweden.
来源:ONCOTARGET
出版年:2014
卷:5
期:7
页码:1829-1836
DOI:10.18632/oncotarget.1829
关键词:Promoter mutation; RCC; TERT; Telomerase; UTUC
摘要:TERT promoter mutations are identified in many malignancies including bladder cancer (BC) and upper tract urothelial carcinoma (UTUC). In contrast, no mutations were found in renal cell carcinoma (RCC) as reported in a recent study. Because the mutant TERT promoter in urine DNA was recently tested as a marker for BC, it is important to ascertain whether these mutations are truly absent in RCCs. Here we determined TERT promoter mutations in 109 patients with RCC and 14 patients with UTUC. The mutations were found in 9/96 (9.3%) clear cell RCC (ccRCC) tumors and 1/8 (13%) chromophobe RCC tumors. Among ccRCC patients, the mutation was correlated with the advanced stages and metastasis, and higher TERT expression. Among UTUCs, the mutation was detected in tumors from 3/5 (60%) patients with renal pelvic cancer and 1/9 (11%) patients with ureter cancer. The mutation was also detected in 1 of 4 urine samples from patients with mutation+ UTUC. Collectively, TERT promoter mutations do occur in RCCs and are associated with aggressive disease. The mutation is more frequent in renal pelvic cancer. Thus, the mutant TERT promoter found in urine may come from not only BC, but also RCC or UTUC.
收录类别:SCOPUS;SCIE
WOS核心被引频次:29
Scopus被引频次:29
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899004976&doi=10.18632%2foncotarget.1829&partnerID=40&md5=3cf723e236054e4c57d9bdcce11cbf81
TOP